Safety and Efficacy Study of Rituximab in Renal Transplantation

November 29, 2007 updated by: Karolinska University Hospital

A Prospective, Randomised, Placebo Controlled, Multicenter Study of the Efficacy and Safety of Rituximab as Induction Therapy Together With Tacrolimus, Mycophenolate Mofetil and Steroids for Patients Undergoing Renal Transplantation

Current strategies for the medical management of transplant patients are largely focused on the prevention and treatment of T-lymphocyte mediated processes. However there is an increasing evidence to suggest that B-lymphocytes have a role in the otherwise classic T-cell mediated rejection of transplants by there ability to act as antigen presenting cells and T-cell activators. Thus there is a significant medical need for effective therapies targeting B cells of transplant patients.One such potential therapy would be to use rituximab, a monoclonal antibody against B-cells in all renal transplant patients. In the present study the efficacy and safety of prophylactic rituximab is studied.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

140

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Stockholm, Sweden, 141 86
        • Transplantation Surgery, Karolinska University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients aged 18 years or above
  • Recipients of first or second renal transplants
  • Recipients of kidneys from living or cadaveric donors
  • Single organ recipients (kidney only)
  • Patients providing written informed consent
  • Patients cooperative and able to complete all the assessment procedures

Exclusion Criteria:

  • Patients receiving other immunosuppressive therapy within the preceding 28 days
  • Recipients of HLA-identical sibling kidneys
  • Patients with flow-PRA >50% within 6 months prior to enrolment
  • Recent history of malignancy
  • Active infection
  • Pregnant or lactating females
  • Women of childbearing potential not willing to use reliable form of contraception

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Composite endpoint of biopsyproven rejection, graft loss or death during the first 6 months following transplanation

Secondary Outcome Measures

Outcome Measure
Renal function at 6 months
Incidence of infections
Incidence of rituximab-related adverse events
Incidence of malignancies

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Gunnar E Tydén, Professor, Karolinska Institutet

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2005

Study Completion (Actual)

October 1, 2007

Study Registration Dates

First Submitted

November 18, 2005

First Submitted That Met QC Criteria

November 18, 2005

First Posted (Estimate)

November 21, 2005

Study Record Updates

Last Update Posted (Estimate)

November 30, 2007

Last Update Submitted That Met QC Criteria

November 29, 2007

Last Verified

October 1, 2007

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe